Teva Pharmaceutical Industries Limited TEVA
TASE · Israel · Health Technology
ILA 12,160.00-150.00 (-1.22%)
Market open· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
CEO Richard Francis says Teva is on track for cost savings and sees a pipeline of new medicines supporting growth beyond 2026.
Branded medicines and biosimilars are reshaping Teva’s revenue mix as management targets faster growth and a sturdier balance sheet.